1. Zoledronate reduces unwanted bone resorption in intercalary bone allografts.
- Author
-
Seo SW, Cho SK, Storer SK, and Lee FY
- Subjects
- Animals, Bone Regeneration drug effects, Bone Remodeling drug effects, Bone Resorption diagnostic imaging, Bone Resorption pathology, Bone Transplantation, Disease Models, Animal, Femur diagnostic imaging, Femur metabolism, Graft Survival drug effects, Graft Survival physiology, Male, Radiography, Rats, Rats, Inbred Lew, Rats, Sprague-Dawley, Transplantation, Homologous, Zoledronic Acid, Bone Density drug effects, Bone Density Conservation Agents pharmacology, Bone Resorption drug therapy, Diphosphonates pharmacology, Femur drug effects, Imidazoles pharmacology
- Abstract
Bone allografts are often hampered by graft incorporation and poor host bone formation. Bisphosphonates, synthetic pyrophosphate analogs, have shown promise in inhibiting bone resorption in human and animal trials. Some in vitro studies have suggested that high dose bisphosphonate may also inhibit bone formation, leading to our hypothesis that an ideal dose of bisphosphonate in allografts could protect allografts from resorption. We transplanted intercalary allografts in to the segmental defect of the rat femurs after soaking each allograft in zoledronate solution (30 microM) and then analysed bone density of the allografts six to 12 weeks after transplantation. At six and 12 weeks, the bone mineral density was higher in the experimental group compared with the control group. Qualitative radiographic and histological analysis also revealed more allograft resorption in the control group than in the zoledronate-treated group. Our data indicate that pharmacological modification of intercalary allografts with zoledronate solution can decrease osteoclast-mediated allograft resorption.
- Published
- 2010
- Full Text
- View/download PDF